Thessaloniki

• A research study to see if kidney damage in people with chronic kidney disease and type 2 diabetes living with overweight or obesity can be … Ended
  2023-505857-42-00 4 2024-04-19 Chronic Kidney Disease, Type 2 diabetes
• A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinet … Ended
  2023-505414-15-00 4 2024-04-10 Dermatitis, Atopic
• A Phase 3 study to assess efficacy and safety of oral tebipenem compared to IV imipenem-cilastatin in adults with cUTI/AP Ended
  2023-503785-22-00 5 2024-03-25 complicated urinary tract infection (cUTI) or acute pyelonephritis (AP
• A study to evaluate SAR441566 efficacy and safety in adults with rheumatoid arthritis Ended
  2023-503910-60-00 4 2024-03-05 Rheumatoid arthritis
• A phase 2b, randomized, double-blind study of redasemtide (S-005151) in adult participants with acute ischemic stroke Ended
  2022-501890-38-00 4 2024-02-16 acute ischemic stroke
• Phase 2 study of SAR444656 in adult participants with moderate to severe atopic dermatitis. Ended
  2023-504346-66-00 4 2024-02-14 Dermatitis atopic
• "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended
  2023-505543-39-00 5 2024-02-12 Chronic Obstructive Pulmonary Disease (COPD)
• A research study to see how well new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar … Ended
  2022-502484-38-00 5 2024-02-07 Type 2 diabetes
• A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib … Ended
  2024-516672-16-00 5 2024-02-02 Multiple Sclerosis
• A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight Ended
  2022-502531-18-00 5 2024-01-18 Obesity
• A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p … Ended
  2023-503333-22-00 5 2024-01-15 Moderate to severe controlled asthma according to Step 4 and Step 5 of
• A Phase 2 study to evaluate the efficacy and safety of SAR444656 compared with placebo in adult participants with moderate to severe hidrade … Ended
  2023-504328-25-00 4 2023-12-27 hidradenitis suppurativa
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the … Ended
  2023-503614-80-00 5 2023-12-14 Pulmonary Arterial Hypertension
• BRIGHT - A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug … Ended
  2022-502001-15-00 4 2023-12-05 Acute Ischemic Stroke (AIS)
• A Multicenter, Adaptive, Randomized, Controlled Trial Platform to Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized … Ended
  2023-504487-41-00 5 2023-11-28 COVID-19
• A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE Ended
  2022-502716-37-00 4 2023-11-27 Recurrent or advanced/metastatic solid tumors who are immunotherapy na
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 5 2023-11-21 Acute Coronary Syndrome
• A study to test the efficacy and safety of SAR442970 in adults with hidradenitis suppurativa Ended
  2022-502370-17-00 4 2023-11-14 Hidradenitis suppurativa
• REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight … Ended
  2022-502678-18-00 5 2023-11-07 Type 2 diabetes
• A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) Ended
  2022-502227-22-00 4 2023-10-25 Autoimmune disease
• A Study to Investigate MBS2320 Patients with IPF Ended
  2023-504418-30-00 4 2023-10-24 Idiopathic Pulmonary Fibrosis
• Study of efficacy and safety of secukinumab in participants with moderate-severe rotator cuff tendinopathy Ended
  2022-502080-38-00 5 2023-10-16 Moderate to severe rotator cuff tendinopathy
• A study to test whether spesolimab helps people with a skin disease called hidradenitis suppurativa Ended
  2022-501074-19-00 10 2023-10-13 Hidradenitis suppurativa
• A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2) Ended
  2022-502837-24-00 5 2023-09-25 Overweight

Showing 529–552 of 655 trials